Literature DB >> 18388497

Persistent factor VIII-dependent factor X activation on endothelial cells is independent of von Willebrand factor.

Herm Jan M Brinkman1, Jan A van Mourik, Koen Mertens.   

Abstract

Endothelial cells are able to support the activation of coagulation factor X by activated factor IX in the presence of its cofactor, factor VIII. We have previously reported that this reaction is persistent on endothelial cells, but transient on activated platelets and phospholipid vesicles when activated factor X (Xa) is used as activator of factor VIII. Aim of the present study was to explore the influence of von Willebrand factor and that of the factor VIII activator, either factor Xa or thrombin, on the decay of factor X activation on the endothelial cell surface. Kinetics of factor X activation on human umbilical vein endothelial cells was compared with that on phospholipid vesicles employing purified coagulation factors from plasma as well as recombinant factor VIII variants. Employing factor Xa as factor VIII activator, rate constants for decay of membrane-bound factor X activation were consistently low on endothelial cells (0.02 min) as compared with phospholipid vesicles (0.2 min). Activation of factor VIII by thrombin resulted in two-fold increased decay rates. In the presence of excess of von Willebrand factor over factor VIII, decay rates were not significantly changed. Factor VIII variants with and without a Tyr to Phe substitution, which abolishes high-affinity binding to von Willebrand factor, displayed the same factor X activation decay kinetics. Although previous studies have shown that von Willebrand factor modulates factor VIII activation and stabilisation, this apparently does not affect the progression of factor X activation at the endothelium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388497     DOI: 10.1097/MBC.0b013e3282faa8c1

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Mitochondrial mitophagy protection combining rivaroxaban and aspirin in high glucose-exposed human coronary artery endothelial cell. An in vitro study.

Authors:  Khaoula Zekri-Nechar; José Javier Zamorano-León; Mercedes Cortina-Gredilla; Ana López-de-Andrés; Rodrigo Jiménez-García; Carlos Navarro-Cuellar; Antonio López-Farré; Carlos Hugo Martínez-Martínez
Journal:  Diab Vasc Dis Res       Date:  2022 Sep-Oct       Impact factor: 3.541

2.  Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension.

Authors:  Claire L Shovlin; Gillian Angus; Richard A Manning; Grace N Okoli; Fatima S Govani; Kay Elderfield; Graeme M Birdsey; Inês G Mollet; Michael A Laffan; Francesco A Mauri
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

3.  Production and control of coagulation proteins for factor X activation in human endothelial cells and fibroblasts.

Authors:  Clay T Cohen; Nancy A Turner; Joel L Moake
Journal:  Sci Rep       Date:  2020-02-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.